Menopausal Hormone Therapy Is Associated With Reduced Total and Visceral Adiposity: The OsteoLaus Cohort. by Papadakis, G.E. et al.
   
 
 
 
 
Serveur Acade´mique Lausannois SERVAL serval.unil.ch
Author Manuscript
Faculty of Biology and Medicine Publication
This paper has been peer-reviewed but does not include the final publisher
proof-corrections or journal pagination.
Published in final edited form as:
Title: Menopausal hormone therapy is associated with reduced total and
visceral adiposity, the OsteoLaus cohort.
Authors: Papadakis GE, Hans D, Rodriguez EG, Vollenweider P, Waeber
G, Marques-Vidal P, Lamy O
Journal: The Journal of clinical endocrinology and metabolism
Year: 2018 Mar 27
DOI: 10.1210/jc.2017-02449
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.
1 
 
Menopausal hormone therapy is associated with reduced total and visceral 1 
adiposity, the OsteoLaus cohort 2 
AUTHORS: Georgios E. Papadakis1, Didier Hans2, Elena Gonzalez Rodriguez 1, 2, Peter Vollenweider3, 3 
Gerard Waeber3, Pedro Marques-Vidal3, Olivier Lamy2, 3 4 
1 Service of Endocrinology, Diabetes and Metabolism, Lausanne University Hospital, Switzerland. 5 
2 Center of Bone Diseases, CHUV, Lausanne University Hospital, Switzerland.   6 
3 Service of Internal Medicine, CHUV, Lausanne University Hospital, Switzerland. 7 
 8 
Short title: MHT reduces fat mass, the OsteoLaus cohort 9 
Key words: menopausal hormone treatment; estrogen; fat mass; visceral adipose tissue; lean mass; 10 
OsteoLaus 11 
Word count (excluding abstract, figure captions, and references): 3925 12 
Number of tables: 4  Figures: 2  References: 40  13 
 14 
Corresponding author’s contact information and address for requests of reprint: 15 
Georgios Papadakis 16 
Service of Endocrinology, Diabetes and Metabolism, CHUV, Lausanne University Hospital 17 
Avenue de la Sallaz 8-10, CH-1011 Lausanne, Switzerland 18 
Phone: +41 79 556 03 08 /+41 79 695 63 48, Fax: +41 21 314 94 51. Email: Georgios.Papadakis@chuv.ch 19 
 20 
DISCLOSURE SUMMARY: None of the authors has any conflicts of interest. 21 
 22 
FUNDING:  23 
The OsteoLaus study was and is supported by research grants from Lausanne University Hospital (CHUV 24 
- Strategic plan funds) and the Swiss National Science Foundation (grants 32473B_156978). The CoLaus 25 
2 
 
study was and is supported by research grants from GlaxoSmithKline, the Faculty of Biology and 26 
Medicine of Lausanne, and the Swiss National Science Foundation (grants 33CSCO-122661, 33CS30-27 
139468 and 33CS30-148401).  28 
These funding sources had no involvement in the study design, data collection, analysis and interpretation, 29 
writing of the report, or decision to submit the article for publication. 30 
 31 
  32 
3 
 
ABSTRACT 33 
Context:  Following menopause fat mass (FM) and visceral adipose tissue (VAT) increase, while non-34 
bone lean mass (LBM) decreases. Whether menopausal hormone therapy (MHT) reverses these changes 35 
remains controversial. 36 
Objective: To assess the effect of MHT on FM, VAT and LBM before and after its withdrawal and 37 
evaluate potential confounders. 38 
Design: Cross-sectional study. 39 
Setting: General community. 40 
Patients or Other Participants: Women of the OsteoLaus cohort (50-80 years old) who underwent dual-41 
energy X-ray absorptiometry (DXA) with body composition assessment. After excluding women with 42 
estrogen-modifying medications, the 1053 participants were categorized into current (CU), past (PU) and 43 
never (NU) MHT users. 44 
Intervention(s): none. 45 
Main Outcome Measure(s): VAT measured by DXA was the primary outcome. We assessed subtotal and 46 
android FM, LBM, muscle strength (hand grip) and confounding factors (caloric intake, physical activity, 47 
biomarkers). 48 
Results: The groups significantly differed in age, NU<CU<PU. Age-adjusted VAT was lower in CU than 49 
PU (p=0.03). CU exhibited lower age-adjusted BMI (-0.9 kg/m2) and a trend for lower FM (-1.3 kg). The 50 
10-year gain of VAT (p< 0.01), subtotal and android FM (p<0.05) was prevented in CU. No difference in 51 
LBM or hand grip was detected. No residual effect was detected for PU, including for early MHT 52 
discontinuers. The confounding factors did not significantly differ between groups except for higher 53 
caloric intake in PU compared with NU. 54 
 Conclusions: MHT is associated with significantly decreased VAT, BMI and android FM. No benefit is 55 
detected for LBM. The benefits are not preserved in PU, suggesting caution when MHT is discontinued. 56 
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PRECIS: 57 
Menopausal hormone therapy is associated with decreased visceral adipose tissue and prevention of the 58 
age-associated gain of fat mass. These benefits are not preserved in past users. 59 
 60 
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INTRODUCTION 61 
Menopause is accompanied by significant changes of bone, fat, and muscular compartments (1, 2). In 62 
particular, menopause transition has been linked to increased propensity for weight gain and fat mass 63 
(FM) accumulation (3, 4). Whether this association is due to declining ovarian hormone secretion or to 64 
ageing remains an open question (2). Data are more robust regarding the effect of menopause on regional 65 
fat. Several prospective studies have shown a stronger increase of abdominal fat after menopause, leading 66 
to a shift from a gynoid to an android pattern of fat distribution (5, 6, 7). The causal association with 67 
estrogen deficiency is supported by preclinical data demonstrating that disruption of estradiol signaling by 68 
deletion of estrogen receptor (ER) or ovariectomy (OVX) accelerates fat accumulation (8). It is important 69 
to underline that excess of central fat, and specifically of visceral adipose tissue (VAT) in humans, is 70 
associated with insulin resistance and high prevalence of metabolic syndrome, which are risk factors for 71 
atherosclerotic cardiovascular disease (9). 72 
A decline in non-bone lean body mass (LBM), also referred as fat-free and skeletal muscle mass, has been 73 
described across menopause (3, 4). It remains unclear whether this finding is a consequence of estrogen 74 
deficiency or indirect factors such a more sedentary lifestyle (10). 75 
Interventional trials assessing the effect of menopausal hormone therapy (MHT) on body composition 76 
have yielded mixed results regarding total FM and LBM (8). Those inconsistent findings can be due to 77 
differences on population studied, studies’ design (natural versus induced menopause), type of MHT and 78 
method for assessing body composition. Conversely, most studies evaluating the effect of GnRH agonists 79 
(GnRHAG), creating an artificial menopause state, have found increased total adiposity and intra-80 
abdominal fat (8). Interestingly, the most recent one (11) showed that this phenotype could be prevented 81 
by estrogen administration.  82 
Another point that remains unclear is whether the eventual impact of MHT on FM is the result of direct 83 
effect on adipocytes or indirect mechanisms such altered energy intake and/or energy expenditure (8) 84 
and/or behavioral effects on mood and anxiety (12) which in turn might affect food intake and physical 85 
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activity. In addition, insulin and adipokines (leptin, adiponectin) have been suggested as potential 86 
modifiers in the crosstalk between reproductive axis and energy homeostasis both centrally and 87 
peripherally (7, 13). 88 
In this cross-sectional study, we assessed the effect of MHT on FM, VAT and LBM before and after its 89 
withdrawal and attempted to explore potential confounders as detailed above. 90 
 91 
MATERIAL AND METHODS: 92 
Setting 93 
We analyzed data from the OsteoLaus study (14). OsteoLaus is a sub-study of the CoLaus study, an 94 
ongoing prospective study aiming to assess the determinants of cardiovascular disease using a population-95 
based sample drawn from the city of Lausanne, Switzerland (15). The aims of the OsteoLaus study are to 96 
compare different models of fracture risk prediction and to assess the relationship between osteoporosis 97 
and cardiovascular diseases. Recruitment of participants of OsteoLaus was detailed previously (16). 98 
CoLaus data (second visit) were collected within 6 months before the OsteoLaus visit. The study was 99 
approved by the Institutional Ethics Committee of the University of Lausanne. All participants signed an 100 
informed consent. 101 
Participants 102 
1500 postmenopausal women, aged 50-80 years, were questioned on current or past MHT use, its type and 103 
duration if applicable. All participants underwent a spine and hip DXA scan by Discovery A System 104 
(Hologic, Inc., Marlborough, MA, USA). We included in this study all the women for whom body 105 
composition assessment was performed during the DXA scan (n=1086). Exclusion criteria were intake of 106 
medication with estrogen-mediated effects (aromatase inhibitors, tamoxifen, antiandrogens), extreme BMI 107 
values (BMI > 37 kg/m2) and uninterpretable or incomplete DXA scans (low quality images). The 108 
remaining participants were divided into 3 groups: current (CU), past (PU) and never users (NU) of MHT. 109 
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CU were taking MHT at trial entry or discontinued treatment since less than 6 months. PU discontinued 110 
MHT at least 6 months before trial entry (otherwise considered as CU). MHT use for less than 6 months, 111 
reported in 25 participants (< 3 months in 23/25), was considered unlikely to cause considerable changes 112 
of body composition and these subjects were classified as NU. 113 
DXA measurements 114 
All body composition measurements were in accordance with published guidelines by International 115 
Society for Clinical Densitometry (17). The subjects were placed in a supine position with palms down 116 
and arms at sides slightly separated from the trunk and correctly centered on the scanning field. Regions 117 
of interest (ROI) were defined by the analytical program including: total body, trunk, head, pelvic, upper 118 
limbs, lower limbs, android and gynoid region. The lower boundary of the android region was defined at 119 
the pelvis cut and the upper boundary above the pelvis cut by 20% of the distance between the pelvis and 120 
chin. The upper boundary of the gynoid ROI was defined below the pelvis cut line by 1.5 times the height 121 
of the android space and gynoid ROI height was equal to 2 times the android ROI height. For each region, 122 
DXA scanned weight of total mass, FM and LBM. VAT was measured as the fat tissue located deep in the 123 
abdomen around the internal organs, as opposed to subcutaneous adipose tissue (SAT). Android lean and 124 
fat mass, gynoid lean and fat mass, and VAT were analyzed in a second step from the initial images of 125 
body composition. For technical reasons, 87 exams could not be reanalyzed rendering the analysis of the 126 
above parameters impossible in these participants.   127 
Outcomes: 128 
Body composition: 1. VAT; 2. Subtotal FM (by extracting head FM from the total FM); 3. Android and 129 
gynoid FM; 4. Fat mass index (FMI) computed as the ratio of total body FM over height squared; 5. LBM: 130 
subtotal, android and gynoid by analogy to FM; 6. Lean mass index (LMI) defined as the ratio of total 131 
LBM over height squared; 7. Sarcopenia indices (18): appendicular lean mass index (ALMI) computed as 132 
the ratio of appendicular lean mass (ALM) over height squared; and ALM divided by body mass index 133 
(ALM/BMI). 134 
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Grip strength: Assessment of muscle strength via handgrip was available for 990 participants. Participants 135 
of the CoLaus aged over 50 were invited to participate in a sub-study on frailty, which included grip 136 
strength, assessed using the Baseline® Hydraulic Hand Dynamometer. Positioning of the participants was 137 
done according to the American Society of Hand Therapists' guidelines (19): subject seated, shoulders 138 
adducted and neutrally rotated, elbow flexed at 90°, forearm in neutral and wrist between 0 and 30° of 139 
dorsiflexion. Three measurements were performed consecutively at the dominant hand and the highest 140 
value (expressed in kg) was used for the analysis. 141 
Potential confounders 142 
Energy intake: Dietary intake was available for 988 participants. Dietary intake was assessed using a self-143 
administered, semi quantitative Food Frequency Questionnaire (FFQ), which has been validated against 144 
24 hour recalls among 626 volunteers from the Geneva population (20). Briefly, this FFQ assesses the 145 
dietary intake of the previous 4 weeks and consists of 97 different food items that account for more than 146 
90% of the intake of calories, proteins, fat, carbohydrates, alcohol, cholesterol, vitamin D and retinol, and 147 
85% of fibre, carotene and iron. Conversion of the FFQ responses into nutrients was based on the French 148 
CIQUAL food composition table. Total energy intake was computed including alcohol consumption. 149 
Sedentarity index: Physical activity was estimated in 901 participants by a self-administered physical 150 
activity frequency questionnaire (PAFQ). The questionnaire lists 70 activities or groups of activities and 151 
was validated against measurement of energy expenditure by heart rate monitor with satisfactory 152 
correlations (r=0.76) between the two methods (21). For this study, only sedentary status (yes/no) was 153 
used. Sedentary status was defined when the participant spent less than 10% of her total daily energy 154 
expenditure in activities with an intensity over 4 basal metabolic rate equivalents. 155 
Hormonal assays: blood sampling was performed at the second CoLaus visit. Most biological assays were 156 
performed by the Lausanne University Hospital (CHUV) Clinical Laboratory on fresh blood samples 157 
within 2 hours of blood collection. Glucose was assessed by glucose dehydrogenase with a maximum 158 
inter-assay and intra-assay coefficient of variation (CV) of 2.1% and 1.0% respectively; Insulin was 159 
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assessed by a solid-phase, two-site chemiluminescent immunometric assay (Diagnostic Products 160 
Corporation, Los Angeles, USA) with a maximum intra-assay CV of 13.7%; HOMA-IR was calculated 161 
according to the formula (glucose × insulin)/22.5. Adiponectin and leptin levels were measured using a 162 
multiplexed particle-based flow cytometric cytokine assay with maximum intra-assay CV of 8.4 and 9.5% 163 
respectively (22). The analysis was conducted using a conventional flow cytometer (Guava EasyCyte 164 
Plus, Millipore, Zug, Switzerland). HOMA-IR and serum adipokines levels were available for 1046 and 165 
977 participants, respectively 166 
Psychiatric assessment: Screening for current or past depression was performed using the Diagnostic 167 
Interview for Genetic Studies (DIGS) as described previously (23). Depression was defined as the 168 
presence of depressive personality disorder or major depressive disorder (single or recurrent episode). 169 
Antidepressant treatment was considered as present for any reported medicine with ATC (Anatomical 170 
Therapeutic Chemical) code beginning with “N06A” (antidepressants) or “N06CA” (antidepressants in 171 
combination with psycholeptics) (https://www.whocc.no/atc_ddd_index/). 172 
Statistical analysis 173 
Statistical analyses were conducted using Stata v14.1 (StataCorp, College Station, Texas, USA) for 174 
Windows. Due to their skewed distributions, leptin and adiponectin concentrations were log transformed 175 
prior to analysis. Descriptive results were expressed as number of participants (percentage) or as average ± 176 
standard deviation. Bivariate analyses were conducted using chi-square for categorical variables and 177 
analysis of variance for continuous variables. Multivariable analyses for continuous variables were 178 
conducted using analysis of variance or multiple regression; results were expressed either as adjusted 179 
average ± standard error or as slope and (95% confidence interval). Post-hoc pairwise comparisons were 180 
performed using Scheffe’s method. Statistical significance was considered for a two-tailed test with a p-181 
value <0.05. 182 
 183 
RESULTS 184 
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Study population 185 
The flowchart of the study is shown in Figure 1. After application of exclusion criteria (n=26), the 186 
remaining 1053 women were classified in the 3 groups: 549 NU (52.14%), 216 CU (20.51%) and 288 PU 187 
(27.35%). Android composition, gynoid composition and VAT were available for 966/1053 participants 188 
(91.7%: 510 NU, 255 PU and 201 CU). 189 
Characteristics of participants 190 
Almost all participants were Caucasian (> 98% for each group). The three groups differed significantly in 191 
age: 66.8 ± 6.3, 62.6 ± 6.7 and 61.3 ± 7.9 years for PU, CU and NU respectively (CU vs. NU: p=0.04; PU 192 
vs. NU: p<0.001). Accordingly, all results were adjusted for age. In the unadjusted analysis, there was a 193 
trend for BMI differences with CU<NU<PU: 24.9 ± 4.1, 25.7 ± 4.3 and 25.8.0 ± 4.3 kg/m2 (CU vs. NU: 194 
p=0.052; CU vs. PU: p=0.049). Average MHT duration was 12.2 ± 8.8 in CU and 7.9 ± 6.3 years in PU. 195 
The latter had an average of 8.5 ± 5.8 years since MHT withdrawal at study entry. 196 
Association between menopausal hormone therapy and measures of body fat, muscle mass and strength 197 
The age-adjusted values of body composition parameters according to MHT are presented in Table 1. CU 198 
exhibited significantly lower VAT values than NU. Similarly, a consistently significant advantage of CU 199 
over NU was found for BMI, android FM, percentage of subtotal FM and FMI (p<0.05). PU showed no 200 
advantage in comparison to NU for all FM outcomes. We did not detect any statistical benefit for the 201 
MHT groups regarding LBM, sarcopenia indices and handgrip strength. On the contrary, there was a trend 202 
for lower LMI in the CU (CU vs. NU, p=0.05). The ratio ALM/BMI was the only parameter that CU 203 
clearly exceeded both PU and NU without reaching statistical significance. 204 
We further performed a regression analysis of different outcomes with age, stratified by MHT group 205 
(Table 2). The slopes for 10-year increments were significantly positive in NU for BMI, subtotal FM, 206 
android FM, VAT and FMI, while being relatively flat for both CU and PU. Between groups comparison 207 
confirmed a significant benefit for both MHT groups (p for interaction < 0.05) for all the above outcomes 208 
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and percentage FM. The most prominent difference was seen for VAT (p=0.01). The associations between 209 
BMI, subtotal FM, android FM and VAT with age are represented in Figure 2. There was no difference 210 
between groups for the slopes of LBM outcomes with tendency for loss of muscle mass in all three 211 
groups. When selectively analyzing women aged < 60 years, no statistical differences persisted between 212 
groups.   213 
Comparison of potential confounders between MHT groups 214 
In an attempt to explore potential confounders, age-adjusted results between MHT groups are shown in 215 
Table 3. No significant difference was detected for glucose, insulin and adipokines levels. Insulin 216 
resistance tended to decrease in treatment groups: CU<PU<NU. Adiponectin was higher in MHT groups 217 
and leptin levels were lower in CU (ns for both parameters). Caloric intake differed between groups but in 218 
favor of NU (NU<CU<PU, NU vs. PU, p=0.039). There was no difference between groups for sedentary 219 
status, prevalence of depression or use of antidepressant medications at study entry.  220 
Subgroup analysis according to MHT duration and time since MHT withdrawal 221 
Table 4 shows the main outcomes of CU according to MHT duration and of PU according to MHT 222 
duration and time since MHT withdrawal. Three subgroups were compared: 0-2, 2-5 and > 5 years. There 223 
was no difference between subgroups for any of the outcomes studied. Similar results were noted when 224 
repeating the analysis of PU between two groups of time since MHT discontinuation: < 5 years versus > 5 225 
years. The effect of time since MHT withdrawal was further explored by a hinge analysis, which did not 226 
identify a reliable inflexion point (data not shown).  227 
 228 
DISCUSSION 229 
Menopausal hormone therapy is associated with lower visceral adiposity 230 
This cross-sectional analysis of the OsteoLaus cohort demonstrated that active MHT use is associated with 231 
significantly lower levels of VAT measured by DXA (Table 1, Supplementary Figure 1). The 232 
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significant increase of VAT with age in NU was completely prevented in CU, suggesting that MHT slows 233 
down the age-associated increase of VAT. These results are in agreement with a recent randomized study 234 
in premenopausal women who experienced an increase in VAT under GnRHAG (11), a phenotype reversed 235 
by estrogen therapy. 236 
Menopause is accompanied by significant changes in body composition (1, 2). Although the menopause-237 
associated bone loss is effectively reversed by MHT (16), the evidence for its effect on FM is less 238 
consistent. Randomized controlled trials have yielded mixed results: some showing a slight decrease of 239 
BMI and total FM by MHT (24, 25), while a subgroup analysis of the WHI trial (26) did not detect any 240 
significant advantage. Despite conflicting results about total FM, most studies detected a reduction of 241 
central fat by MHT as indicated by reduced waist circumference (25), decrease in DXA-measured trunk to 242 
leg fat ratio (26), lower waist-to-hip ratio (27), reduced trunk FM measured by whole-body CT (28) and 243 
reduced DXA-measured android fat (29). Several small studies have assessed the effect of MHT on VAT, 244 
as reviewed by Santen et al (30). The majority showed reduced VAT, except for a randomized placebo-245 
controlled study in non-obese, early postmenopausal women (31) which showed no benefit of MHT for 246 
intra-abdominal fat (assessed by CT at L4-L5 vertebral disk level). This result was potentially attributed to 247 
the continuous estrogen/progestin regimen used in this study and an accompanying decrease in insulin 248 
sensitivity, even though another prospective non-randomized study implementing a continuous MHT 249 
regimen detected a benefit regarding android shift of fat distribution (27). 250 
Current users of menopausal hormone therapy have lower BMI, FMI and android fat 251 
Our data also pointed out a slight but significant superiority of CU regarding lower BMI, android fat and 252 
FMI. Interestingly, all the studies showing significant decrease of total and/or central adiposity recruited 253 
early post-menopausal women (25, 26, 28), whereas differences were less pronounced in older 254 
populations as in the WHI trial (average age > 63 years). It is possible that the beneficial effect of MHT on 255 
FM is more pronounced in the early postmenopausal period and that age-mediated changes overcome the 256 
MHT benefits later in life. Of notice, even in the studies with significant benefits the effect size was small. 257 
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The only published metanalysis (32) showed a significant reduction of waist circumference and abdominal 258 
fat (measured by dual energy photon or DXA) by 0.8% (5 trials) and 6.8% (4 trials), respectively. 259 
Menopausal hormonal therapy prevents the age-associated gain of body fat 260 
The benefit of MHT was confirmed in the regression analysis, which highlighted a clear divergence 261 
between CU and NU regarding the association between age and body fat parameters. Indeed, NU had 262 
significantly larger slopes for increase of BMI, subtotal and android FM, as well as FMI. MHT prevented 263 
significantly the age-associated increase of the above parameters. This type of analysis offers the benefit 264 
of a projection over time, going beyond the limits of a simple crossectional analysis. 265 
Potential confounders do not seem to explain the MHT effect on fat mass 266 
It remains controversial whether the beneficial effect of MHT on FM is due to a direct effect on 267 
adipocytes, mediated by other hormones or by modifying intermediary factors such as nutrition and/or 268 
physical activity. In the current study, CU tended to be less sedentary (61.4% versus 65.4 and 67.6 for NU 269 
and PU respectively) without reaching statistical significance. Caloric intake was significantly higher in 270 
PU than in NU; CU did not differ from the other two groups. Despite findings of positive correlations 271 
between E2 and leptin independently of body fat in one study of premenopausal women (33), adipokines 272 
levels did not differ significantly in our cohort after adjustment for age and subtotal FM (data not shown). 273 
Finally, no difference was found regarding prevalence of depression between groups. 274 
Existing evidence on regulation of energy intake and expenditure by estrogens has been recently reviewed 275 
by Leeners et al (34). Strong preclinical data support an important role for estrogen in bioenergetics. Both 276 
OVX mice and rats exhibited a marked reduction of spontaneous physical activity and a decrease in 277 
resting energy expenditure (REE), while OVX rats developed an additional increase in energy intake (8). 278 
The latter was not seen in OVX mice, in line with our data in NU. In menstruating women, REE is higher 279 
in mid-luteal phase when E2 is elevated, low in early follicular phase when E2 is lower and further 280 
reduced by GnRHAG (35). An indirect effect via increase of sedentarity was postulated by Lovejoy et al. 281 
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who prospectively followed physical activity annually by accelerometry in women going through 282 
menopause and detected a decrease of 50% over 4 years (4). 283 
The benefit of menopausal hormone therapy on fat mass does not seem to persist after its withdrawal 284 
Another interesting point of our study is the clear absence of residual effect of MHT in PU. PU were 285 
classified according to MHT duration and time since MHT discontinuation; this analysis surprisingly 286 
showed no residual effect in early discontinuers, unlike our results regarding BMD (16) and suggesting a 287 
very rapid rebound effect following MHT withdrawal. However, the regression analysis detected 288 
significantly less steep slopes in PU than in NU for multiple FM outcomes, a result that deserves further 289 
exploration by a longitudinal study. To the best of our knowledge, no other study has specifically assessed 290 
body composition in PU. Studies with GnRHAG (11, 36) have shown significant increases of total and 291 
central adiposity as soon as 4 months after estrogen withdrawal, consistent with our hypothesis of a rapid 292 
rebound effect. The rapid response of FM to external stimuli is also illustrated by the early  increase of 293 
FM (+ 21.3%) only 8 weeks after training cessation in elite Taekwondo athletes (37). The observed 294 
increase in caloric intake of PU in our study provides another possible explanation for the rapid loss of 295 
FM benefits after MHT withdrawal. It would be reasonable to suggest confirmation of these results in the 296 
setting of a randomized trial to eliminate contribution of a selection bias. 297 
Menopausal hormone therapy does not have any detectable benefit on lean mass 298 
We hypothesized that MHT leads to increased LBM, which in turn would contribute to its favorable bone 299 
effects via increased mechanical load. Strongly positive correlations between LBM and BMD, previously 300 
demonstrated (29, 38), support a potential link. Surprisingly we did not detect any benefit among MHT 301 
users for LBM nor muscle strength. These results were confirmed even after excluding women with 302 
osteoporotic drugs other than MHT (n=82, data not shown), thus arguing against an intermediate role of 303 
LBM in the MHT-mediated bone benefits.  304 
Our results add to the already existing conflicting evidence of available studies with the only available 305 
metanalysis (33) showing a slight but significant increase (+3.3%) of LBM in MHT users. One possible 306 
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explanation might be the type of MHT. Certain progestagens, such as the norethisterone acetate used by 307 
Arabi et al (29) have androgenic properties that could have anabolic effect on LBM. More importantly, 308 
the effect of MHT on LBM can be selective for early post-menopausal women, weaning off rapidly under 309 
the stronger effect of age. In favor of this hypothesis, the WHI trial revealed that MHT significantly 310 
delayed loss of LBM after 3 years (28). Nevertheless, this relation was completely reversed between year 311 
3 and 6 of the study, with a light decrease of LBM in all groups at the end of year 6 (39), a finding also 312 
confirmed in the subset of women with high compliance. In our analysis, no LBM benefit was revealed 313 
when analyzing only younger post-menopausal women (< 60 years old). It is possible that this time-314 
dependent effect is limited to a much shorter period after menopause (for example, up to 5 years) as 315 
suggested by the studies discussed above (28, 39). 316 
Strengths and limitations 317 
This study has several limitations. The crossectional design is inevitably accompanied by a selection bias. 318 
Information on the beginning and the end of MHT was self-reported. This was also the case for the route 319 
of administration (oral, transdermal, vaginal), the type of MHT (estrogen-alone or estrogen/progestin) and 320 
the history of hysterectomy, preventing us from reliably assessing these factors. Further, we were unable 321 
to verify the adherence of participants to MHT. The vast majority of participants were Caucasians, 322 
limiting the generalization of study's conclusions to other ethnicities. Our evaluation of confounding 323 
factors is partial. The physical activity assessment was only rough. We did not measure resting energy 324 
expenditure, which is a potential target of estrogen treatment.  325 
On the other hand, our study has considerable strengths to be taken into account. The large sample of the 326 
OsteoLaus cohort allows for adequate statistical power. Body composition assessment was performed by 327 
DXA using last generation software which allowed for reliable measurement of VAT, differentiating it 328 
from SAT (40). To the best of our knowledge, this is the first large prospective study of postmenopausal 329 
women that has explored the MHT effect on VAT by reliably distinguishing it from other components of 330 
fat tissue. 331 
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In conclusion, current MHT use prevents the increase of visceral adiposity. This finding may have 332 
important cardiovascular, metabolic and bone implications which should be taken into account when 333 
assessing the benefit-risk ratio for MHT prescription. Nevertheless, the effect size on BMI and total FM is 334 
relatively small and MHT prescription cannot substitute for other interventions such as physical activity. 335 
Physicians should be aware that the benefit of MHT on body composition might rapidly disappear after its 336 
withdrawal and strongly encourage women to optimize nutrition and increase physical activity when 337 
stopping MHT. Future research via prospective and ideally randomized studies should assess differences 338 
depending on type of MHT and route of administration as well as the evolution of body composition after 339 
MHT withdrawal. It would also be interesting to specifically investigate the effects of MHT on body 340 
composition in populations with an ethnically diverse composition as well as in early postmenopausal 341 
women.  342 
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LEGEND OF FIGURE 1 459 
Flow chart of the study highlighting the inclusion and exclusion criteria. Out of the 1500 postmenopausal 460 
women of OsteoLaus with DXA scan, body composition assessment was retrievable in 1086 women who 461 
were included for the current analysis. 462 
Abbreviations: BMI, Body mass index; DXA, Dual energy X-ray absorptiometry; E2, estrogen. 463 
 464 
LEGEND OF FIGURE 2 465 
Linear association between age at study inclusion and body mass index (panel A), subtotal fat mass (panel 466 
B), android fat mass (panel C) and visceral adipose tissue (panel D), according to menopausal hormone 467 
therapy group. Results are expressed as slope and 95% confidence interval for current users (light grey), 468 
past users (medium grey) and never users (dark grey). 469 
 470 
 471 
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TABLES: 472 
Table 1: Age-adjusted values of body composition parameters according to menopausal hormone therapy status. 473 
 Never users Past users Current users 
Global    
p-value CU vs. NU CU vs. PU PU vs. NU 
Sample size 549 288 216     
Body mass index (kg/m2) 25.8 ± 0.2 25.6 ± 0.3 24.9 ± 0.3 0.03 0.03 0.21 0.78 
Fat mass (kg)        
Subtotal 23.3 ± 0.3 23.3 ± 0.5 22.0 ± 0.5 0.05 0.06 0.14 0.99 
Android 2.01 ± 0.04 2.00 ± 0.06 1.83 ± 0.06 0.02 0.03 0.12 0.97 
Gynoid 4.64 ± 0.05 4.71 ± 0.08 4.48 ± 0.08 0.13 0.29 0.13 0.74 
Visceral  0.48 ± 0.01 0.48 ± 0.02 0.42 ± 0.02 0.01 0.02 0.07 0.98 
Fat mass (% total body weight)        
Subtotal  35.9 ± 0.3 36.2 ± 0.4 34.6 ± 0.4 0.01 0.03 0.03 0.90 
Lean mass (kg)        
Subtotal  40.2 ± 0.2 39.8 ± 0.3 40.1 ± 0.4 0.62 0.95 0.86 0.62 
Android 3.20 ± 0.02 3.17 ± 0.03 3.12 ± 0.04 0.24 0.24 0.60 0.86 
Gynoid 6.36 ± 0.04 6.34 ± 0.06 6.29 ± 0.06 0.63 0.63 0.85 0.95 
Fat mass index (kg/m2) 10.1 ± 0.1 10.0 ± 0.2 9.4 ± 0.2 0.01 0.02 0.08 0.95 
Lean mass index (kg/m2) 15.9 ± 0.1 15.7 ± 0.1 15.5 ± 0.1 0.04 0.05 0.64 0.37 
ALMI (kg/m2) 6.6 ± 0.04 6.5 ± 0.05 6.5 ± 0.06 0.08 0.12 0.85 0.35 
ALM/BMI 6795 ± 47 6815 ± 68 6978 ± 74 0.10 0.11 0.27 0.97 
Hand grip strength (kg) 24.6 ± 0.2 23.9 ± 0.3 24.5 ± 0.4 0.19 0.97 0.43 0.20 
Results are expressed as age-adjusted mean ± standard error. PU, past users; NU, never users; CU, current users; ALMI, appendicular lean mass 474 
index; ALM, appendicular lean mass. Between-group comparisons performed using analysis of variance; post-hoc pairwise comparisons 475 
performed using Scheffe’s method. 476 
 477 
  478 
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Table 2: Regression between the body composition variables and age at study inclusion (10-year increments), stratified by menopausal hormone 479 
therapy status 480 
 481 
 482 
 483 
 484 
 485 
 486 
 487 
 488 
 489 
 490 
 491 
 492 
 493 
ALMI, appendicular lean mass index; § p-value for interaction. Results are expressed in slope (95% confidence interval) for a ten-year increment. 494 
Significant (p<0.05) slopes are indicated in Bold. Statistical analysis by linear regression and interaction analysis by ANCOVA. 495 
  496 
 Never Past Current P-value § 
Sample size 549 288 216  
Body mass index (kg/m2) 0.97 (0.52 ; 1.41) -0.15 (-0.94 ; 0.63) 0.15 (-0.68 ; 0.97) 0.025 
Fat mass (kg)     
Subtotal 1.78 (1.00 ; 2.57) -0.21 (-1.55 ; 1.13) 0.19 (-1.28 ; 1.66) 0.018 
Android 0.18 (0.08 ; 0.27) 0.02 (-0.15 ; 0.18) -0.08 (-0.25 ; 0.09) 0.023 
Gynoid 0.04 (-0.10 ; 0.18) -0.15 (-0.37 ; 0.08) -0.05 (-0.29 ; 0.19) 0.375 
Visceral 0.10 (0.07 ; 0.12) 0.05 (-0.01 ; 0.09) 0.02 (-0.03 ; 0.07) 0.014 
Fat mass (% total body weight)     
Subtotal 2.13 (1.48 ; 2.79) 0.75 (-0.36 ; 1.85) 0.54 (-0.73 ; 1.80) 0.022 
Lean mass (kg)     
Subtotal  -0.66 (-1.23 ; -0.09) -1.55 (-2.44 ; -0.65) -0.62 (-1.67 ; 0.44) 0.258 
Android 0.01 (-0.06 ; 0.07) -0.06 (-0.16 ; 0.04) -0.08 (-0.19 ; 0.03) 0.322 
Gynoid -0.17 (-0.27 ; -0.06) -0.24 (-0.40 ; -0.08) -0.20 (-0.38 ; -0.02) 0.771 
Fat mass index (kg/m2) 0.80 (0.47 ; 1.12) 0.15 (-0.42 ; 0.71) 0.09 (-0.50 ; 0.69) 0.041 
Lean mass index (kg/m2) 0.13 (-0.07 ; 0.34) -0.24 (-0.55 ; 0.08) -0.12 (-0.52 ; 0.28) 0.143 
ALMI (kg/m2) -0.15 (-0.11 ; 0.08) -0.17 (-0.31 ; -0.02) -0.14 (-0.32 ; 0.03) 0.180 
25 
 
Table 3: Age-adjusted values for possible confounders of body composition parameters, stratified by menopausal hormone therapy status 497 
 Never Past Current Global, p-value 
Sample size* 549 288 216  
Glucose (mmol/l) 5.76 ± 0.04 5.65 ± 0.05 5.65 ± 0.06 0.18 
Insulin (mU/l) 7.67 ± 0.23 7.31 ± 0.32 7.06 ± 0.36 0.32 
HOMA-IR 2.04 ± 0.08 1.94 ± 0.11 1.88 ± 0.13 0.53 
Leptin (pg/ml) 6782 ± 276 7414 ± 385 5965 ± 434 0.19§ 
Adiponectin (ng/ml) 6406 ± 234 6709 ± 327 6697 ± 369 0.24§ 
Total caloric intake (kcal) 1613 ± 31 1751 ± 43 1655 ± 48 0.04 
Current smoking, yes (%) 20.9 15.5 16.7 0.12 
Sedentary (n=471) (n=241) (n=189)  
Yes (%) 65.4 67.6 61.4 0.40 
No (%) 34.6 32.4 38.6  
Depression prevalence (n=363) (n=168) (n=147)  
Yes (%) 51.5 54.2 57.8 0.43 
Antidepressant medications, yes (%) 11.8 14.2 15.3 0.37 
*The exact sample size differs according to the parameter analyzed (glucose, n=1048; insulin, n=1046; HOMA-IR, n=1046; leptin, n=977; 498 
adiponectin, n=977; total caloric intake, n=988; sedentarity index, n=901; depression scale, n=678). 499 
Results are expressed as age-adjusted mean ± standard error or as percentages for sedentarity and depression prevalence. MHT, menopausal 500 
hormone treatment. Between-group comparisons performed using analysis of variance. §Statistical analysis performed on log-transformed data. 501 
  502 
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Table 4: Body composition parameters in menopausal hormone therapy past users according to duration of and time since discontinuation. 503 
 BMI (kg/m2) Subtotal FM (kg) Subtotal FM (%) Android fat (kg) VAT (kg) FMI (kg/m2) 
CURRENT USERS 
Sample size 215 215 215 200 200 200 
Duration of MHT (years) 
[0-2] 24.51 ± 0.97 20.34 ± 1.73 33.14 ± 1.49 1.76 ± 0.19 0.39 ± 0.06 9.12 ± 0.67 
[2-5] 24.62 ± 0.69 20.74 ± 1.23 34.52 ± 1.06 1.81 ± 0.14 0.41 ± 0.04 9.43 ± 0.48 
[5+] 25.02 ± 0.36 22.5 ± 0.65 34.76 ± 0.56 1.84 ± 0.08 0.43 ± 0.02 9.42 ± 0.27 
P-value 0.856 0.389 0.614 0.924 0.827 0.910 
PAST USERS      
Sample size 274 274 274 242 242 242 
Duration of MHT (years)      
[0-2] 26.71 ± 0.72 24.18 ± 1.22 36.38 ± 1.01 2.10 ± 0.14 0.54 ± 0.04 10.47 ± 0.51 
[2-5] 25.39 ± 0.62 23.94 ± 1.05 36.70 ± 0.86 2.00 ± 0.13 0.49 ± 0.04 10.04 ± 0.47 
[5+] 25.67 ± 0.33 23.48 ± 0.57 36.76 ± 0.47 2.03 ± 0.07 0.50 ± 0.02 10.23 ± 0.25 
P-value 0.334 0.850 0.946 0.878 0.588 0.816 
Time since discontinuation (years)      
[0-2] 25.72 ± 0.82 24.17  ± 1.40 36.40 ± 1.15 2.14 ± 0.17 0.53 ± 0.05 10.32 ± 0.60 
[2-5] 25.69 ± 0.63 23.54 ± 1.08 36.80 ± 0.89 2.03 ± 0.14 0.51 ± 0.04 10.21 ± 0.49 
[5+] 25.81 ± 0.32 23.63 ± 0.55 36.71 ±  0.45 2.02 ± 0.07 0.50 ± 0.02 10.22 ± 0.24 
P-value 0.985 0.927 0.960 0.807 0.813 0.988 
MHT, menopausal hormone therapy; BMI, body mass index; FM, fat mass; VAT, visceral adipose tissue; FMI, FM index.  Results are expressed 504 
as adjusted mean ± standard error. Statistical analysis was performed using an ANOVA model including age, body mass index, duration of 505 
menopausal hormonal therapy and time since discontinuation. 506 
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FIGURE 1: Flow chart of the study 507 
 508 
 509 
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FIGURE 2: Graphic representation of regression analysis of different outcomes with age at study 510 
inclusion according to menopausal hormone therapy status 511 
 512 
 513 
 514 
 515 
 516 
 517 
 518 
  519 
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SUPPLEMENTARY FIGURE 1: Age-adjusted values of visceral adipose tissue stratified by menopausal hormone therapy status. 520 
 521 
LEGEND OF SUPPLEMENTARY FIGURE 1 522 
Graphic representation of age-adjusted values of visceral adipose tissue (VAT) according to menopausal hormone therapy (MHT) status. The 523 
results are shown as histograms corresponding to mean VAT values, accompanied by vertical bars corresponding to standard errors. Each MHT 524 
30 
 
groups is portrayed by a different color: current users (light grey), past users (medium grey) and never users (dark grey). When comparing current 525 
to never users, a statistically significant difference was seen (p<0.05). 526 
 527 
